AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00817297 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: noninvasive ventilator
Description: Experimental V60 Mask noninvasive Ventilator for treating patients with COPD, then Comparator Conventional Mask noninvasive Ventilator for treating patients with COPD in crossover study design
Study NCT04065048 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soy based diet
Description: The diet will be based on the detailed descriptions according to the American Heart Association, US Food and Drug Administration (FDA), and the Soyfoods Association of North America Website, which all promote soy products as having beneficial nutrient profiles with a daily consumption of 25 grams or more of soy protein (average serving = 6.25 grams), upper limit of 50g.
Study NCT04065048 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-soy based diet
Description: Diet of identical composition to the soy diet with the exception of soy.
Study NCT03379675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-53718678 500 mg
Description: Participants will receive 500 mg dose of JNJ-53718678 oral solution once daily for 7 days.
Study NCT03379675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-53718678 80 mg
Description: Participants will receive 80 mg dose of JNJ-53718678 oral solution along with the matching placebo to the same total volume as for the 500 mg dose once daily for 7 days.
Study NCT03379675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: In treatment B, participants will receive matching placebo along with JNJ-53718678 to maintain the same total volume as for the 500 mg dose once daily for 7 days. In treatment C, participants will receive matching placebo to the same total volume as for the 500 mg dose once daily for 7 days.
Study NCT03379675 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In treatment B, participants will receive matching placebo along with JNJ-53718678 to maintain the same total volume as for the 500 mg dose once daily for 7 days. In treatment C, participants will receive matching placebo to the same total volume as for the 500 mg dose once daily for 7 days.
Study NCT03868215 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Next-generation sequencing (NGS)
Description: NGS test for colorectal tumor-specific plasma ctDNA methylation markers prior to endoscopy and before surgical resection.
Study NCT04079361 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood samples
Description: Bood samples during prenatal and postnatal visits
Study NCT03850379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: This is a prospective study comparing consecutive patients who will be be receiving ciprofloxacin prophylaxis vs. levofloxacin prophylaxis for Stem cell transplant till engraftment defined as ANC >1000
Study NCT03850379 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: This is a prospective study comparing consecutive patients who will be be receiving ciprofloxacin prophylaxis vs. levofloxacin prophylaxis for Stem cell transplant till engraftment defined as ANC >1000
Study NCT02390245 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Free Eye Screenings
Description: This group will receive free eye screening and follow-up comprehensive ophthalmic exam if recommended.
Study NCT04446416 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NaviFUS System
Description: Open the BBB using focused ultrasound and contrast agent SonoVue®
Study NCT04446416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: An anti-angiogenic agent to block tumor growth
Study NCT04375150 — intervention group
Intervention type: DRUG
Intervention: Tyrosine kinase inhibitor (TKI)
Description: TKIs
Study NCT04375150 — intervention group
Intervention type: DRUG
Intervention: Immuno-oncology (IO)
Description: IOs
Study NCT04105036 — intervention group
Intervention type: OTHER
Intervention: Data Collection
Description: Telephone interview questionnaire, in-home face-to-face interview, and data from the Collection Site
Study NCT03405883 — intervention group
Intervention type: OTHER
Intervention: Vaginal swab + endometrial biopsy
Description: In the midluteal phase of the cycle, a vaginal swab (E swab) and endometrial biopsy (TAO brush) will be obtained.
Study NCT03891706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tumor-specific TCR-T cells
Description: On day 0 and day 14, 0.5-5x10\^9 TCR-T cells will be infused intravenously (IV) over 1 hour,patients may choose to receive more cell infusions if they benefit from the treatment.
Study NCT03891706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Aldesleukin 3,000,000 IU. IV.QD beginning within 24 hours of cell infusion and continuing for up to 5 days .
Study NCT04014829 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pain-Pressure Threshold
Description: Performed on bilateral trapezius muscles. Pressure will be applied at 90 degrees downward with an algometer, with the speed of pressure increase approximately 1kgf/s. Upon the sensation of pain, the patient will vocalize or raise her hand to terminate the test, and the highest reading will be recorded (up to maximum 6kgf). If two values are recorded within 0.2kgf of each other, the mean value will be recorded. If two values are greater than 0.2kgf of each other, a third test will be performed and the mean obtained.
Study NCT04014829 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Mechanical Temporal Summation
Description: Pinprick hyperalgesia will be evoked using a Von Frey filament, applied to the volar aspect of the dominant forearm. Participants will report using the numerical rating scale the intensity of pain from the first stimulus. Subsequently, ten repetitive stimuli one second apart will be applied with the same filament within an area of 1cm diameter of the same forearm. Subjects will report the rate the pain intensity of the tenth stimulus. The magnitude of MTS is calculated as the difference between the last to the first pain scores. The investigators will classify the participants according to evoked MTS if the last stimulus is rated higher than the first, or no MTS if the last stimulus is rated equal or lower than the first. The research team administering the test will follow a set script.
Study NCT04014829 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Hospital Anxiety and Depression Scale
Description: Standardized questionnaire to determine the level of anxiety and depression.
Study NCT04014829 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pain Catastrophizing Scale
Description: Standardized questionnaire to determine the level of pain catastrophizing.
Study NCT04014829 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Central Sensitization Inventory
Description: Standardized questionnaire to determine the level of central sensitization.
Study NCT04014829 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fear-Avoidance Component Score
Description: Standardized questionnaire to determine the level of fear and avoidance.
Study NCT04014829 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: EQ-5D
Description: Standardized questionnaire to assess generic health-related quality of life.
Study NCT04014829 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: heart rate variability
Description: Heart rate variability will be determined from the R-to-R intervals obtained from a 5-minute ECG recording.
Study NCT04014829 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Anxiety, anticipated pain, anticipated analgesia
Description: Preoperative anxiety (0 to 100), anticipated pain (0 to 100), and anticipated analgesia requirement (0 to 5).
Study NCT04014829 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: State-trait anxiety inventory
Description: Standardized questionnaire to assess anxiety.
Study NCT04014829 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Beck's Depression Inventory
Description: Standardized questionnaire to assess depressive symptoms.
Study NCT04482179 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active TMS
Description: Active TMS will be delivered at 100% motor threshold
Study NCT04482179 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CILT
Description: 60-90 minutes of CILT will be administered during each treatment session
Study NCT04482179 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: CILT
Description: 60-90 minutes of CILT will be administered during each treatment session
Study NCT04482179 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TMS
Description: Sham TMS will be administered
Study NCT02997631 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MEDi Robot
Description: Distraction therapy using an interactive humanoid robot
Study NCT01274793 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mosapride Citrate tablet
Description: Orally administered 5 mg mosapride citrate tablet s three times a day for 4 continuous weeks if no severe adverse effects were found.
Study NCT01274793 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-dose acupuncture
Description: In this low current intensity group, the current applied would be relatively weak,it was clearly perceived by the participants
Study NCT01274793 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-dose acupuncture
Description: In this group,the current was strong enough to reach the patients'tolerance threshold value.
Study NCT02070575 — intervention group
Intervention type: OTHER
Intervention: blood draw
Description: Venous blood will be collected in an EDTA Vacutainer tubeup to 10 mL and will be immediately put on ice. This sample may be drawn as a stand-alone blood draw. Samples will be centrifuged at 1900g (3000-3200 RPM) for 15 Minutes and the serum aliquoted into freezer vials and stored at -80°C until analysis. In addition patients who have not received treatment for biochemical recurrence after their first draw are eligible for subsequent draws to determine the reproducibility of the test over time.
Study NCT01968447 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hypocapnia
Description: Hyperventilation to the level of hypocapnia
Study NCT01968447 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: normocapnia
Description: Normal ventilation to the level of nromocapnia
Study NCT04193046 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood Sample
Description: Prevalent (existing) and incident (new) participants who are found to either have PH or not by RHC will provide blood sample for the establishment of a biomarker signature of PH.
Study NCT03547518 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PTNS treatment
Description: One-week induction consisting of three active PTNS treatments, each 2 hours long
Study NCT03547518 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham treatment
Description: One-week induction consisting of three active PTNS treatments, each 2 hours long
Study NCT02390245 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Intervention
Description: This group will receive ophthalmic referral and a navigator for assistance in scheduling appointments; confirming appointments via phone, mail, email and/or text message; arranging transportation through Customized Community Transportation (CCT) and Philadelphia Paratransit Service; and trained medical interpreters as needed.
Study NCT02390245 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: This group will receive ophthalmic referral.
Study NCT02179697 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Patient's Choice
Description: Patient chooses between surgery plus bracing or bracing alone. The patient will be followed according to the same schedule as Group 1.
Study NCT02179697 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery + Bracing vs. Bracing Alone
Description: Surgery + Bracing vs. Bracing Alone
Study NCT02953652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HBI-8000
Description: Orally twice weekly
Study NCT03128866 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemipelvectomy
Description: Undergo hemipelvectomy
Study NCT03128866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Given IV
Study NCT04066283 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: There was no intervention in this study
Study NCT04648033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atovaquone Oral Suspension
Description: Atovaquone, cisplatin and vinorelbine are all considered Investigational Medicinal Products (IMPs) in this trial due to the investigation of these drugs in a novel combination. Patients will be allocated one of four doses of atovaquone: 450 mg, 600 mg, 675 mg or 750 mg (all doses PO BD).
Study NCT04648033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care chemotherapy
Description: Atovaquone, cisplatin and vinorelbine are all considered Investigational Medicinal Products (IMPs) in this trial due to the investigation of these drugs in a novel combination. Patients will receive two 21-day cycles of cisplatin and vinorelbine chemotherapy, comprising 80 mg/m2 cisplatin on days 1 \& 22 of their CRT treatment and 15 mg/m2 vinorelbine on days 1, 8, 22 \& 29.
Study NCT04648033 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Standard of care radiotherapy
Description: Thoracic radiotherapy will commence on day one of chemotherapy and be delivered in 66 Gy in 33 fractions, once daily, 5 days a week (Monday-Friday) for 6.5 weeks.
Study NCT04323956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT04323956 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV
Study NCT04323956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT04323956 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT04323956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parsaclisib
Description: Given PO
Study NCT04323956 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Parsaclisib
Description: Given PO
Study NCT04323956 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Given SC
Study NCT04323956 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pegfilgrastim
Description: Given SC
Study NCT04621318 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab
Description: 60 mg, single-dose
Study NCT04621318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: 60 mg, single-dose
Study NCT02880891 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prothetic procedure
Description: splinted crown
Study NCT03273296 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Amoxicillin (po) 500 mg x 3 per day for 3 days.
Study NCT04323956 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polatuzumab Vedotin
Description: Given IV
Study NCT04323956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO
Study NCT04323956 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Given PO
Study NCT04323956 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT04323956 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Given IV
Study NCT04323956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT04323956 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT00981656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 60-minute intravenous (IV) infusion of 15 mg/m\^2 on days 1, 2, 3, 15, 16, 17, 29, 30, and 31 of radiation treatment.
Study NCT00981656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: Continuous IV infusion of 500 mg/m\^2/24 hrs for 5 consecutive days during weeks 1 and 4 of radiation treatment.
Study NCT00981656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin
Description: IV bolus dose of 12 mg/m\^2 on day 1 of radiation treatment.
Study NCT00981656 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Three-Dimensional Conformal Radiation Therapy
Description: Total dose to the gross bladder volume of 61.2 Gy as 34 daily fractions 5 days/week, for approximately 7 weeks.
Study NCT04077801 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: diagnostic test
Description: diagnostic test
Study NCT04077801 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Postpartum pain
Description: test
Study NCT04077801 — intervention group
Intervention type: OTHER
Intervention: Visual analogue scale
Description: test TMJ /pelvic angle/lumber angle
Study NCT03273296 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Azithromycin (po) 500 mg x 1 on day 1, 250 mg x 1 on day 2, and 250 mg x 1 on day 3.
Study NCT03273296 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Vancomycin (po) 125 mg x 4 per day for 3 days.
Study NCT02616640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Study NCT04858087 — intervention group
Intervention type: OTHER
Intervention: Screening and treatment
Description: Students were screened by mRDTs and treated with artemether-lumefantrine if positive
Study NCT02616640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Study NCT02616640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT03949569 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapy Dog
Description: Children will undergo a 5 minute unstructured session with either a certified therapy dog or with a dog who is trained and certified for animal-assisted interventions and/or animal-assisted activities. Children will be allowed to talk to, pet, and play with the therapy dog during the interaction.
Study NCT03949569 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stuffed Toy Dog
Description: Children will undergo a 5 minute unstructured session with a stuffed toy dog. Children will be allowed to talk to, pet, and play with the stuffed toy dog during the interaction.
Study NCT03949569 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5 Minute Puppy Video
Description: Children will watch a 5 minute puppy video.
Study NCT04443413 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam Radiation Therapy
Description: Undergo proton beam radiation therapy
Study NCT04443413 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04443413 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: X-ray Therapy
Description: Undergo x-ray therapy
Study NCT03839524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG4050
Description: Subcutaneous injections weekly for the first 6 weeks and then every 3 weeks.
Study NCT00460226 — intervention group
Intervention type: DRUG
Intervention: lamotrigine
Description: lamotrigine treatment for 12weeks
Study NCT02816944 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS-guided laser ablation for refractory neoplasms
Study NCT00323323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHOP
Description: CHOP will be given 60-120 minutes following SQ administration of Alemtuzumab as follows: cyclophosphamide 750 mg/m2 IV on day 1, doxorubicin 50 mg/m2 IV on day 1, vincristine 1.4 mg/m2 (maximum dose = 2 mg) IV on day 1, and prednisone 100 mg PO on days 1-5.
Study NCT00323323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Single agent Alemtuzumab given subcutaneously (SQ) on week #1. Dose escalation will occur during the first week of therapy, starting with 3 mg of Alemtuzumab administered SQ on day 1. If well tolerated, this will be followed by 10 mg SQ on day 3 and 30 mg (split into 2 injection sites) on day 5.
Study NCT00323323 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plasma Samples
Description: Plasma samples will be obtained for Alemtuzumab pharmacokinetics (PK) during the first week of single agent Alemtuzumab stepped up dosing and subsequently before and after the 5th and the 8th Alemtuzumab/CHOP dose.
Study NCT03696160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biktarvy
Description: Integrase inhibitor used to treat HIV-1 infection
Study NCT03696160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Symtuza
Description: Protease inhibitor used to treat HIV-1 infection
Study NCT02275702 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone IV
Description: It will be administered at the induction of the anesthesia
Study NCT02275702 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution